Insider · SEC Forms 3, 4, 5
CIK 1494730
All transactions
Every Form 4 row this person reported, newest first
Insider · SEC Forms 3, 4, 5
Every Form 4 row this person reported, newest first
Collins Helen Louise (CIK 1701247) reported 36 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-21). Recent activity: Sell ELVN (2,916 shares), Buy ELVN (5,000 shares), Sell ELVN (1,844 shares), Sell ELVN (240 shares), Buy ELVN (5,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,916 | $145,891 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 1,844 | $93,507 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 240 | $12,356 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 3,900 | $227,650 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 1,100 | $65,281 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 63 | $3,397 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 231 | $11,563 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 459 | $23,660 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,063 | $108,085 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,184 | $116,669 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 1,268 | $54,308 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 1,133 | $50,690 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,599 | $114,018 |
| 2026-05-20 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-05-20 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 3,475 | $137,367 |
| 2026-05-20 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 1,302 | $52,406 |
| 2026-05-20 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 223 | $9,190 |
| 2026-04-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,441 | $117,314 |
| 2026-04-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Buy | 5,000 | $12,400 |
| 2026-04-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 140 | $6,413 |
| 2026-04-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | Sell | 2,419 | $114,636 |
Source: SEC Form 4 filings · as of 2026-09-21